An Evaluation of the Efficacy of HEXI-PREP by Clinell Wipes

Antimicrobial Effect Clinical Trial

Official title:

An Evaluation of the Efficacy of HEXI-PREP by Clinell Wipes Versus Placebo and Chloraprep, for Use in Preoperative Skin Preparation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03417661
• Other study ID #: GH001
• Status: Completed
• Phase: Phase 3
• Start date: June 29, 2018
• Est. completion date: September 18, 2019

Study information

• Verified date: July 2020
• Source: Gama Healthcare Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the antimicrobial properties of HEXI-PREP by Clinell compared to both a negative and a positive control product.

Description:

HEXI-PREP by Clinell is a sterile single sachet wipe containing chlorhexidine gluconate and isopropyl alcohol. Both active ingredients are well-established ingredients commonly used for their disinfectant properties.

This trial is designed to assess the superiority of HEXI-PREP by Clinell Wipe against a negative control, and also to demonstrate the relative efficacy of HEXI-PREP by Clinell WIpe against a similar commercially available product.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 93
• Est. completion date: September 18, 2019
• Est. primary completion date: June 6, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Male and female participants 18 - 70 years, who have provided written informed consent to participate in the study

• Test sites with a bacterial baseline count of = 5.0 log10/cm2 at the inguinal (groin) test administration sites. =4.0 log10/cm2 at the abdominal test site and >3.0 log10/cm2 at the clavicular and/or median cubital regions at Day - 5 of screening

• Participants, who in the opinion of the Investigator, are in suitable health for inclusion in the study.

Exclusion Criteria:

• Exposure of the test sites to strong detergents, solvents or other irritants during the 14- day pre-test conditioning period or during the test period.

• Use of systemic or topical antibiotic medications, steroid medications or any other product known to affect the normal microbial flora of the skin, up to 1 month prior to the screening period, during the 14-day pre-test conditioning period or during the test period.

• Any known allergies to latex (rubber), alcohols, tape adhesives or to common antibacterial agents found in soaps, lotions or ointments, particularly chlorhexidine gluconate or chlorine.

• Active skin rashes or breaks in the skin at the test site.

• Active skin diseases or inflammatory skin conditions including contact dermatitis within 10cm of the test site.

• Showering or bathing after the Day -5 baseline sampling and unwilling to refrain from showering or bathing whilst at Surrey CRC (Day 0 to Day 1).

• Participation in another clinical trial within 90 days preceding randomisation.

• Pregnant or breastfeeding women.

• Any other medical condition, which in the opinion of the Investigator, should preclude participation.

• Unwillingness to fulfil the performance requirements of the study.

Related Conditions & MeSH terms

• Antimicrobial Effect

Intervention

Drug:
• HEXI-PREP By Clinell Wipes
Sterile single sachet wipe containing 3ml solution.
• Chloraprep
Sterile applicator containing 3ml solution.
• Placebos
Sterile saline (0.9% w/v) wipe, containing 3ml of solution.

Locations

Country	Name	City	State
United Kingdom	Surrey Clinical Research Centre	Guildford	Surrey

Sponsors (1)

Lead Sponsor	Collaborator
Gama Healthcare Ltd.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction of bacterial load at each test site.	Reduction in bacterial load of the test product in comparison to a negative control.	1 and 10 minutes after application.
Secondary	Persistence of reduction in bacterial load at each test site.	Reduction in bacterial load of the test product in comparison to a negative control over a longer duration.	30 minutes - 24 hours
Secondary	Relative efficacy compared to a positive control	To assess the reduction in bacterial load after application when compared to a similar commercially available product.	1-10 minutes, and 30 minutes - 24 hours
Secondary	Number of participants with treatment-related adverse events as assessed by a 5-point scale based on comment from the participant, and recorded assessments of erythema and oedema.	Assessed by comments from the participant logged on a five-point scale, and recorded assessments of erythema and oedema by the investigator. Erythema and oedema are each assessed on a five-point scale of none to severe.	From application